Serum TIMP-1 Predicts Survival Outcomes of Invasive Breast Carcinoma Patients: A Meta-analysis

Archives of Medical Research

Volumn 42, Issue 6, 2011, Pages 463-468

  Lee, Ju Han ^a   Choi, Jung Woo ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Breast cancer; Meta analysis; Survival; TIMP 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INVASION; CANCER PATIENT; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; NEOPLASM INVASIVENESS; RNA, MESSENGER; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 82855182179     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.09.006     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Thomssen C., Janicke F. Do we need better prognostic factors in node-negative breast cancer?. Pro Eur J Cancer 2000, 36:293-298.
3. Hayakawa T., Yamashita K., Tanzawa K., et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992, 298:29-32.
4. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994, 86:299-304.
5. Guedez L., Courtemanch L., Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998, 92:1342-1349.
6. Kim Y.S., Seo D.W., Kong S.K., et al. TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation. Cancer Lett 2008, 269:37-45.
7. Lee S.J., Yoo H.J., Bae Y.S., et al. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 2003, 312:1196-1201.
8. Liu X.W., Bernardo M.M., Fridman R., et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003, 278:40364-40372.
9. Liu X.W., Taube M.E., Jung K.K., et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005, 65:898-906.
10. Talvensaari-Mattila A., Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat 2005, 89:29-34.
11. Wurtz S.O., Moller S., Mouridsen H., et al. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol Cell Proteomics 2008, 7:424-430.
12. Lipton A., Leitzel K., Chaudri-Ross H.A., et al. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 2008, 26:2653-2658.
13. Wu Z.S., Wu Q., Yang J.H., et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 122:2050-2056.
14. Schrohl A.S., Holten-Andersen M.N., Peters H.A., et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004, 10:2289-2298.
15. McCarthy K., Maguire T., McGreal G., et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999, 84:44-48.
16. Sieuwerts A.M., Usher P.A., Meijer-van Gelder M.E., et al. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 2007, 53:1280-1288.
17. Nakopoulou L., Giannopoulou I., Stefanaki K., et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002, 197:307-313.
18. Willemoe G.L., Hertel P.B., Bartels A., et al. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. Eur J Cancer 2009, 45:2528-2536.
19. Zhang B., Cao X., Liu Y., et al. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008, 8:83.
20. Vizoso F.J., Gonzalez L.O., Corte M.D., et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007, 96:903-911.
21. Kuvaja P., Talvensaari-Mattila A., Paakko P., et al. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma. Oncology 2005, 68:196-203.
22. Nakopoulou L., Giannopoulou I., Lazaris A., et al. The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003, 111:1027-1036.
23. Kuskunovic S., Radovic S., Doric M., et al. Immunohistochemical expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in invasive breast carcinoma. Bosn J Basic Med Sci 2009, 9:125-130.
24. Del Casar J.M., Gonzalez L.O., Alvarez E., et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 2009, 116:39-52.
25. Zhang Y.G., Du J., Tian X.X., et al. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas. Chin Med J 2007, 120:1597-1605.
26. Normand S.L. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999, 18:321-359.
27. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
28. Lee J.H., Lee E.S., Kim Y.S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007, 110:38-46.
29. Lee J.H., Kim S.H., Lee E.S., et al. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep 2009, 22:1149-1156.
30. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267-283.
31. Lambert E., Dasse E., Haye B., et al. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004, 49:187-198.
32. Holten-Andersen M.N., Stephens R.W., Nielsen H.J., et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000, 6:4292-4299.
33. Yoshikawa T., Saitoh M., Tsuburaya A., et al. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer 1999, 86:1929-1935.
34. Jung K.K., Liu X.W., Chirco R., et al. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006, 25:3934-3942.
35. Wurtz S.O., Schrohl A.S., Mouridsen H., et al. TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol 2008, 47:580-590.
36. Sorensen I.V., Fenger C., Winther H., et al. Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 2006, 54:1075-1086.